Impact of availability of a highly effective Cystic Fibrosis treatment (elexacaftor/tezacaftor/ivacaftor) on lung transplant waitlist and lung transplantation trends in the US

Pulmonary Fibrosis

LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis

J Cyst Fibros

Vega-Hernandez G, MacGregor G, Wilfin A, Adams F, Haugh C, Baxter CA, Wöhling H, Clarke SL, Charman SC, Carr SB

doi: 10.1016/j.jcf.2025.04.012

RECOMMENDED

Pulmonary Fibrosis

The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

★ 2 Recommended by Dr Martin Frey, Faculty Member

Lancet Respir Med

Burgel PR, Sermet-Gaudelus I, Girodon E, Durieu I, Houdouin V, Audousset C, Macey J, Grenet D, Porzio M, Murris-Espin M, Reix P, Baravalle M, Belleguic C, Mely L, Verhille J, Weiss L, Reynaud-Gaubert M, Mittaine M, Hamidfar R, Ramel S, Cosson L, Douvry B, Danner-Boucher I, Foucaud P, Roy C, Burnet E, Raynal C, Audrezet MP, Da Silva J, Martin C, French Cystic Fibrosis Reference Network study group

doi: 10.1016/S2213-2600(24)00208-X

RECOMMENDED

Pulmonary Fibrosis

Effect of elexacaftor/tezacaftor/ivacaftor on systemic inflammation in cystic fibrosis

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Thorax

Maher RE, Cytlak-Chaudhuri UM, Aleem S, Barry P, Brice DP, Caamaño Gutiérrez E, Driver K, Emmott E, Rothwell A, Smith E, Travis M, Lee D, McNamara PS, Waller I, Smith JA, Jones A, Lord RW

doi: 10.1136/thorax-2024-222242

RECOMMENDED

Pulmonary Fibrosis

Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

★ 2 Recommended by Dr Martin Frey, Faculty Member

Lancet Respir Med

Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M, Sutharsan S, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Floreth T, Michelson P, Sosnay PR, Nair N, Zahigian R, Martin H, Ahluwalia N, Lam A, Horsley A

doi: 10.1016/S2213-2600(24)00411-9

Pulmonary Fibrosis

Real-World Effectiveness and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients with Phe508del -Gating and -Residual Function Genotypes

Respir Med

Salvatore D, Iacotucci P, Pepe A, Terminiello A, Majo F, Carnovale V, Vitullo P, Messore B, Parisi GF, Calderazzo MA, Leonetti G, Terlizzi V

doi: 10.1016/j.rmed.2025.108221

RECOMMENDED

Pulmonary Fibrosis

Longer term follow-up of abdominal symptoms (CFAbd-Score) after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

J Cyst Fibros

Caley LR, Gillgrass L, Zagoya C, Saumtally H, Duckstein F, H W, Mainz JG, Peckham DG

doi: 10.1016/j.jcf.2025.01.010

Pulmonary FibrosisFurther Publications

Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study

Ther Adv Respir Dis

Pepe A, Fevola C, Dolce D, Campana S, Ravenni N, Taccetti G, Salvatore D, Terlizzi V

doi: 10.1177/17534666251314706

RECOMMENDED

Further Publications

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Extension Study

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Am J Respir Crit Care Med

Daines CL, Polineni D, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, Quon BS, Ringshausen FC, Selvadurai H, Taylor-Cousar JL, Withers NJ, Sawicki GS, Lee T, Ahluwalia N, Morlando Geiger J, Jennings M, Tan YV, Waltz D, Ramsey B, Griese M, VX17-445-105 Study Group

doi: 10.1164/rccm.202411-2231OC

RECOMMENDED

Pulmonary Fibrosis

Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Thorax

Merlo CA, Thorat T, DerSarkissian M, McGarry LJ, Nguyen C, Gu YM, Healy J, Rubin JL, Brookhart MA

doi: 10.1136/thorax-2023-220558

Related content

LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis

The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

Effect of elexacaftor/tezacaftor/ivacaftor on systemic inflammation in cystic fibrosis

Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

Real-World Effectiveness and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients with Phe508del -Gating and -Residual Function Genotypes

Longer term follow-up of abdominal symptoms (CFAbd-Score) after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis

Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Extension Study

Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis